From detection to action: Transparency, accuracy, and integration for clinical artificial intelligence in musculoskeletal aging Authors: Ta-Wei Tai, Dung Van Tran Published: 2026 A recent collaboration between Vietnam and Taiwan marks the opening of a new chapter in musculoskeletal care. Nearly 2000 pelvic and hip radiographs obtained during routine care in central Vietnam were analyzed by an artificial intelligence (AI) system developed in Taiwan for osteoporosis screening [1]. The study illustrates how AI can extract additional clinical information from images obtained during routine care, enabling earlier identification of individuals who might otherwise remain unscreened. AI may accelerate screening, automate selected screening tasks, extend clinical capacity, and support case finding in regions where dual-energy X-ray absorptiometry (DXA) and trained personnel are limited. At the same time, important questions remain about how clinicians should interpret AI outputs, judge their reliability, and connect detection to appropriate care. These questions motivate this Special Issue. The four contributions in this Special Issue show how AI is being explored across musculoskeletal care. They examine automated muscle assessment after hip fracture, osteoporosis screening from chest radiographs, vertebral compression fracture detection, and knee osteoarthritis grading and reporting [[2], [3], [4], [5]]. All use medical images to detect or quantify clinically relevant features of bone, muscle, or joints. Together, they reflect a field that is advancing but is not yet part of routine care in most settings, with uneven study quality and reporting across the broader osteoporosis AI literature [6]. For clinicians, the first interpretive pitfall is to equate strong technical performance with a clinically useful test. The area under the receiver operating characteristic curve (AUC) summarizes overall discrimination, but it does not show whether risks are calibrated, whether the threshold fits the clinical purpose, or how many patients will undergo unnecessary testing. The relevant performance measure depends on the intended use and the consequences of false-negative and false-positive results. AI also creates a black-box problem. Explanations may help clinicians assess whether an output is clinically plausible, but they do not replace validation [7]. Before acting, clinicians should know the target population and condition, the operating threshold, the uncertainty, the likely consequences of errors, and the required confirmatory assessment. The Asia-Pacific consensus statement provides detailed guidance on the validation, reporting, ethical use, and clinical implementation of AI in osteoporosis care [8]. For clinicians, however, practical assessment can begin with three simple principles: transparency, accuracy, and integration.•Transparency. The intended use, inputs, outputs, target population, and decision threshold should be clear. Clinicians should know whether the system estimates risk, flags an abnormality, measures anatomy, or generates text. Explanations should direct attention to findings that can be clinically verified, while poor image quality, missing inputs, uncertainty, and out-of-scope cases should remain visible [8].•Accuracy. The relevant performance target must match the intended clinical task. For an AI system used to screen for bone lesions, including metastases or tumors, high sensitivity may be prioritized because missed lesions could delay further assessment. In community-based osteoporosis screening, however, positive predictive value and referral yield become especially important: too many false-positive results would lead to unnecessary DXA referrals and increase downstream clinical workload. The operating threshold should therefore balance missed cases against avoidable referrals. External validation should also assess calibration and performance across clinically relevant populations, institutions, and devices; results from development data should not be assumed to generalize to new settings [9].•Integration. Clinicians should ask where the output enters the workflow, who receives it, and what action it is intended to trigger. These decisions should be specified before model development begins. Every actionable output should then connect to a predefined pathway for confirmatory assessment, referral or treatment, communication, and follow-up [8]. Whether the goal is to identify patients who would otherwise be missed or to reduce clinical workload, integration must be purposeful and linked to a measurable benefit in routine care. •Transparency. The intended use, inputs, outputs, target population, and decision threshold should be clear. Clinicians should know whether the system estimates risk, flags an abnormality, measures anatomy, or generates text. Explanations should direct attention to findings that can be clinically verified, while poor image quality, missing inputs, uncertainty, and out-of-scope cases should remain visible [8]. Transparency. The intended use, inputs, outputs, target population, and decision threshold should be clear. Clinicians should know whether the system estimates risk, flags an abnormality, measures anatomy, or generates text. Explanations should direct attention to findings that can be clinically verified, while poor image quality, missing inputs, uncertainty, and out-of-scope cases should remain visible [8]. •Accuracy. The relevant performance target must match the intended clinical task. For an AI system used to screen for bone lesions, including metastases or tumors, high sensitivity may be prioritized because missed lesions could delay further assessment. In community-based osteoporosis screening, however, positive predictive value and referral yield become especially important: too many false-positive results would lead to unnecessary DXA referrals and increase downstream clinical workload. The operating threshold should therefore balance missed cases against avoidable referrals. External validation should also assess calibration and performance across clinically relevant populations, institutions, and devices; results from development data should not be assumed to generalize to new settings [9]. Accuracy. The relevant performance target must match the intended clinical task. For an AI system used to screen for bone lesions, including metastases or tumors, high sensitivity may be prioritized because missed lesions could delay further assessment. In community-based osteoporosis screening, however, positive predictive value and referral yield become especially important: too many false-positive results would lead to unnecessary DXA referrals and increase downstream clinical workload. The operating threshold should therefore balance missed cases against avoidable referrals. External validation should also assess calibration and performance across clinically relevant populations, institutions, and devices; results from development data should not be assumed to generalize to new settings [9]. •Integration. Clinicians should ask where the output enters the workflow, who receives it, and what action it is intended to trigger. These decisions should be specified before model development begins. Every actionable output should then connect to a predefined pathway for confirmatory assessment, referral or treatment, communication, and follow-up [8]. Whether the goal is to identify patients who would otherwise be missed or to reduce clinical workload, integration must be purposeful and linked to a measurable benefit in routine care. Integration. Clinicians should ask where the output enters the workflow, who receives it, and what action it is intended to trigger. These decisions should be specified before model development begins. Every actionable output should then connect to a predefined pathway for confirmatory assessment, referral or treatment, communication, and follow-up [8]. Whether the goal is to identify patients who would otherwise be missed or to reduce clinical workload, integration must be purposeful and linked to a measurable benefit in routine care. Ultimately, the clinical value of AI depends on whether detection leads to appropriate care. Experience with fracture liaison services demonstrates that organized pathways can increase bone density testing, treatment initiation, and adherence while reducing refracture and mortality after fragility fractures [10]. AI should be integrated into similarly organized pathways to find patients earlier, reduce missed opportunities, and streamline avoidable clinical work. It should not become another unconnected alert. AI may find more, but outcomes will improve only when detection is linked to an effective treatment pathway. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work, the authors used OpenAI Codex to assist with content organization, reference checking, and language polishing. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. Conflicts of interest Ta-Wei Tai has received honoraria for lectures and attending meetings from Amgen, Alvogen/Lotus, Zimmer-Biomet and United Orthopedics. Dung Van Tran has no conflicts of interest to declare.